Medical Training & Education Services was Zhongchao’s largest product and service line in fiscal 2025, bringing in $6.86M of $12.07M (57%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Medical Training & Education Services | $6.60M | $6.39M | $7.70M | $6.86M | |
| Patient Management Services In Patient-Aid Projects | $6.29M | $4.02M | $6.01M | $3.82M | |
| Sales Of Patented Drugs | $1.22M | $9.03M | $2.15M | $696.44K | |
| Product | $1.22M | $9.03M | $2.15M | $696.44K | |
| Other Revenues | $42.33K | — | — | — | |
| Total | $15.37M | $28.46M | $18.02M | $12.07M |
Zhongchao brought in $12.07M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 33.0% from $18.02M in fiscal 2024. Medical Training & Education Services was the largest at $6.86M (56.8%), ahead of Patient Management Services In Patient-Aid Projects at $3.82M (31.6%) and Sales Of Patented Drugs at $696.44K (5.8%). The remaining line, Product, brought in $696.44K.
Compared with fiscal 2024, every line above 2% of revenue shrank. Medical Training & Education Services held up best, down 11.0% to $6.86M, and Product fell the most, down 67.6% to $696.44K.
Zhongchao stopped reporting Other Revenues as a separate line after fiscal 2022, when it brought in $42.33K.
Mdmooc Services was Zhongchao’s largest segment in fiscal 2025, bringing in $10.68M of $11.37M (94%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Mdmooc Services | $12.94M | $10.41M | $13.71M | $10.68M |
| Sales Of Patented Drugs | $1.22M | $9.03M | $2.15M | $696.44K |
| Total | $14.15M | $19.43M | $15.86M | $11.37M |
Zhongchao brought in $11.37M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $12.07M it reports by product and service, so these segments do not cover all of its revenue. Mdmooc Services was the largest at $10.68M (93.9%), ahead of Sales Of Patented Drugs at $696.44K (6.1%).
Compared with fiscal 2024, Mdmooc Services fell 22.1% to $10.68M and Sales Of Patented Drugs fell 67.6% to $696.44K.
Zhongchao (ZCMD) reports its revenue by product and service and by segment. In fiscal 2025, Medical Training & Education Services was its largest product and service line, bringing in $6.86M (56.8% of the total), followed by Patient Management Services In Patient-Aid Projects at $3.82M (31.6%).
Medical Training & Education Services was Zhongchao's largest product and service line in fiscal 2025, bringing in $6.86M, or 56.8% of the $12.07M total across its four product and service lines.
Mdmooc Services was Zhongchao's largest segment in fiscal 2025, bringing in $10.68M, or 93.9% of the $11.37M total across its two segments.
Every figure comes from Zhongchao's annual financial filings, as reported. Each line keeps the name Zhongchao gives it, and years follow its fiscal calendar.
Zhongchao's revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.